Athira pharma reports fourth quarter and full year 2020 financial results and provides business highlights

– lift-ad and act-ad studies evaluating ath-1017, a once-daily investigational drug for the treatment of mild-to-moderate alzheimer's disease, actively enrolling patients –

ATHA Ratings Summary

ATHA Quant Ranking